πŸ‡ΊπŸ‡Έ FDA
Patent

US 10907160

Methods for reducing LRRK2 expression

granted A61KA61K31/7115A61K31/712

Quick answer

US patent 10907160 (Methods for reducing LRRK2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
48
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125, A61P